Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …

Tau and amyloid beta (Aβ) are the prime suspects for driving pathology in Alzheimer's
disease (AD) and, as such, have become the focus of therapeutic development. Recent …

Amyloid-ß (Aß) is best known as the misfolded peptide that is involved in the pathogenesis
of Alzheimer's disease (AD), and it is currently the primary therapeutic target in attempts to …

Since its discovery in 1984, the beta amyloid peptide has treaded the boards of
neurosciences as the star molecule in Alzheimer's disease pathogenesis. In the last decade …

Amyloid-beta (Aß) and hyperphosphorylated tau are hallmark lesions of Alzheimer's disease
(AD). However, the loss of synapses and dysfunctions of neurotransmission are more …

Alzheimer's disease (AD) is the most common form of dementia in the elderly, and affects
millions of people worldwide. As the number of AD cases continues to increase in both …

Alzheimer's disease (AD) is the most common cause of dementia associated with a
progressive neurodegenerative disorder, with a prevalence of 44 million people throughout …

The dominant hypothesis of Alzheimer's disease (AD) aetiology, the neuropathological
guidelines for diagnosing AD and the majority of high-profile therapeutic efforts, in both …

The microbiota–gut–brain axis plays an important role in the development of
neurodegenerative diseases. Commensal and pathogenic enteric bacteria can influence …

Amyloidogenesis has been implicated in a broad spectrum of diseases in which amyloid
protein is invariably misfolded and deposited in cells and organs. Alzheimer's disease is one …